IP Library Granted Patent US 7,456,318
Granted Patent B2
US 7,456,318 · App. 11/722,767 · Granted Nov 25, 2008

Process for preparing benzylated amines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,456,318
App. No.
11/722,767
Granted
Nov 25, 2008
Kind
B2
Abstract

This present invention relates to a process for preparing benzylated amines by the reaction of an amine selected from methamphetamine and propylhexedrine with benzyl halide. Numerous improvements are obtained by employing the amine in molar excess with respect to benzyl halide, preferably in a molar ratio of 2 to 1. The excess amine is employed to selectively neutralize by-product acid as the amine salt. The amine salt is then separated from the reaction mixture and basified to reclaim starting amine for recycle to the process.

Claims (42)

1. A process for the preparation of a benzylated amine with the co-production of by-product hydrogen halide, by the reaction of an amine selected from the group consisting of methamphetamine and propylhexedrine with a benzyl halide in a reaction vessel wherein said amine is in molar excess with respect to the benzyl halide and such excess reacts with by-product hydrogen halide to produce an amine halide.

2. The process of claim 1 wherein the molar ratio of amine to benzyl halide is about 2 to 1.

3. The process of claim 1 wherein the amine hydrogen halide is separated from the reaction mixture by solid/liquid separation means.

4. The process of claim 3 wherein the separation is performed by filtration means.

5. The process of claim 3 further including the step of basifying the amine hydrogen halide and recovering amine.

6. The process of claim 5 further including the step of recycling the amine to the reaction vessel.

7. The process of claim 1 further including the step of adding a diluent to the reaction mixture.

8. The process of claim 7 wherein the diluent is selected from the group consisting of toluene, xylenes, and chlorobenzene.

9. The process of claim 8 wherein the diluent is toluene.

10. The process of claim 1 wherein the amine hydrogen halide is dissolved in water and separated from the reaction mixture by liquid/liquid separation means.

11. The process of claim 1 further including the step of initially purging the reaction vessel with nitrogen.

12. The process of claim 1 wherein the halide is chlorine.

13. A process for preparing benzphetamine with the co-production of by-product hydrogen chloride by the reaction of methamphetamine with benzyl chloride comprising the steps of:

A) combining the methamphetamine with benzyl chloride in a molar ratio of about 2 to 1, respectively, in a reaction vessel to produce benzphetamine and by-product hydrogen chloride;

B) allowing the excess methamphetamine to react with by-product hydrogen chloride to produce a reaction mixture containing benzphetamine and methamphetamine hydrochloride salt;

C) separating said methamphetamine hydrochloride salt from the reaction mixture;

D) basifying methamphetamine hydrochloride to provide methamphetamine and isolating said methamphetamine, then;

E) recycling the methamphetamine of step D to step A.

14. The process of claim 13 further including the step of providing an organic solvent diluent in steps A or B and in step C.

15. The process of claim 14 further including the steps, after separating said methamphetamine hydrochloride salt, of acidifying the remainder of the reaction mixture whereby said benzphetamine is converted to an acid salt, adding water to said reaction mixture to dissolve said acid salt and then separating the newly formed salt in water solution by liquid/liquid separation.

16. The process of claim 14 wherein the diluent is selected from the group consisting of toluene, xylenes, and chlorobenzene.

17. The process of claim 16 wherein the diluent is toluene.

18. The process of claim 14 further including in step C washing the separated methamphetamine hydrochloride to recover benzphetamine.

19. The process of claim 18 wherein the separated methamphetamine hydrochloride is washed with a washing agent selected from the group consisting of toluene, xylenes, benzene, and chlorobenzene.

20. The process of claim 19 wherein the washing agent is toluene.

21. The process of claim 13 wherein the methamphetamine hydrochloride is separated in step C by liquid/liquid separation by adding a sufficient amount of water so as to dissolve the methamphetamine hydrochloride and then separating the methamphetamine hydrochloride from the reaction mixture by liquid/liquid separation means.

22. The process of claims 13 further including the step of initialing purging the reaction vessel with nitrogen.

23. A process for preparing N-benzylpropylhexedrine with the co-production of by-product hydrogen chloride by the reaction of propylhexedrine with benzyl chloride comprising the steps of:

A) combining the propylhexedrine with a benzyl chloride in a reaction vessel in a molar ratio of about 2 to 1, respectively to produce N-benzylpropylhexedrine and by-product hydrogen chloride;

B) allowing the excess propylhexedrine to react with by-product hydrogen chloride to produce propylhexedrine hydrochloride to produce a reaction mixture containing N-benzylpropylhexedrine and propylhexedrine hydrochloride salt;

C) separating said propylhexedrine hydrochloride from the reaction mixture;

D) basifying propylhexedrine hydrochloride to provide propylhexedrine and isolating said propylhexedrine, then;

E) recycling the propylhexedrine of step D to step A.

24. The process of claim 22 further including the step of providing a diluent in steps A or B and in step C.

25. The process of claims 24 further including the steps, after separating said propyhexedrine hydrochloride, of acidifying the remainder of the reaction mixture whereby said N-benzylpropylhexedrine is converted to an acid salt, adding water to said reaction mixture to dissolve said acid salt and then separating the newly formed salt in water solution by liquid/liquid separation.

26. The process of claim 24 wherein the diluent is selected from the group consisting of toluene, xylenes, and chlorobenzene.

27. The process of claims 26 wherein the diluent is toluene.

28. The process of claim 23 further including in step C washing the separated propylhexedrine hydrochloride to recover N-benzylpropylhexedrine.

29. The process of claim 28 wherein the separated propylhexedrine hydrochloride is washed with a washing agent selected from the group consisting of toluene, xylenes, benzene, and chlorobenzene.

30. The process of claim 29 wherein the washing agent is toluene.

31. The process of claim 23 wherein step C includes the step of adding a sufficient amount of water so as to dissolve the propylhexedrine hydrochloride and then separating the propylhexedrine hydrochloride from the reaction mixture by liquid/liquid separation means.

32. The process of claims 23 further including the step of initialing purging the reaction vessel with nitrogen.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2007
From: KALOTA, DENNIS J.
To: MALLINCKRODT INC.
Reel/Frame 019479/0560 →